RxDoctor Payments DataLook up a doctor →

Edmund Waller, MD

Hematology · Atlanta, GANPI 1366550931

Payments from drug & device makers

$2,833,196in general payments, 2019–2025

Across 475 payments — averaging $5964.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$1.5M
  • Bristol Myers Squibb$363K
  • Novartis$331K
  • Sanofi US Services Inc.$123K
  • National Marrow Donor Program$107K
  • Partner Therapeutics, Inc.$97K
  • plus $312K from 23 others
$5,358in research payments, 2019–2025

Across 5 payments — averaging $1071.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$5K
  • Pharmacyclics LLC, An Abbvie Company$120

What the payments were for

  • Consulting fees$73,35862%
  • Speaking & faculty fees$32,44327%
  • Travel & lodging$6,8166%
  • Food & beverage$6,3945%
  • Education$2000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,833,196 in reported general payments places this provider in the 90th percentile of 27 hematology providers in Georgia.

See all hematology providers in Georgia

Medicare billing

Part B allowed, 2024
$18,400
Medicare patients
51
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezurockBelumosudil Mesylate80$1,605,431
BrukinsaZanubrutinib24$362,170
PrevymisLetermovir33$240,087
JakafiRuxolitinib Phosphate17$234,630
Sirolimus11$2,603
ValacyclovirValacyclovir Hcl29$1,130
Tacrolimus12$675
Acyclovir46$563
Fluconazole12$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCRezurock$17,075$1,605,43180 claims
Incyte CorporationJakafi$4,251$234,63017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 27 hematology providers in Georgia.

Other hematology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →